Chargement de la fiche…
Chargement de la fiche…
rhumatologie
Activité mixte
Paris (75017)
Anti-IL-23 · Sjögren · Biothérapies non-anti-TNF
Tout est calculé à partir des sources publiques (RPPS, PubMed, OpenAlex, OpenStreetMap…) — aucun classement éditorial.
Côté patient
Comprendre votre pathologie, exercices à domicile, applications validées, paramédicaux à proximité — gratuit, sans inscription.
DES Rhumatologie · Rhumatologie (SM) — Diplôme d'Études Spécialisées
DE Docteur en médecine — Capacité / Certificat d'Études Spéciales
2026Rheumatology and therapy
PubMed ↗Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study
2025Rheumatology (Oxford, England)
PubMed ↗Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS
2025Frontiers in immunology
PubMed ↗Guselkumab binding to CD64(+) IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling
2025Rheumatology and therapy
PubMed ↗Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study
2024Therapeutic advances in musculoskeletal disease
PubMed ↗Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial
2024Clinical rheumatology
PubMed ↗Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
2024Alimentary pharmacology & therapeutics
PubMed ↗Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
2024Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis
2024RMD open
PubMed ↗Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
2024Rheumatology and therapy
PubMed ↗Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
2023Arthritis research & therapy
PubMed ↗Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
2023Rheumatology (Oxford, England)
PubMed ↗Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
2023Arthritis research & therapy
PubMed ↗Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
2023Annals of the rheumatic diseases
PubMed ↗Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'
2023Arthritis research & therapy
PubMed ↗Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study
2023Arthritis research & therapy
PubMed ↗Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
2023Annals of the rheumatic diseases
PubMed ↗Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
2023RMD open
PubMed ↗Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
2022The lancet. Gastroenterology & hepatology
PubMed ↗Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
2022Annals of the rheumatic diseases
PubMed ↗Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
2026Bulletin du cancer
PubMed ↗[Which access in France to innovative treatments and testing for patients with cancer?]
2024Joint bone spine
PubMed ↗Hurdles in new drug development in rheumatic diseases
2019Drug discovery today
PubMed ↗Physicians in the pharmaceutical industry: their roles, motivations, and perspectives
2009Joint bone spine
PubMed ↗Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: development of recommendations for clinical practice based on published evidence and expert opinion
2009Joint bone spine
PubMed ↗Diagnosis of peripheral psoriatic arthritis: recommendations for clinical practice based on data from the literature and experts opinion
2009Joint bone spine
PubMed ↗Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion
2008Annals of the rheumatic diseases
PubMed ↗The development of a preliminary ultrasonographic scoring system for features of hand osteoarthritis
2007Joint bone spine
PubMed ↗Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
2007Joint bone spine
PubMed ↗Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
2007Joint bone spine
PubMed ↗Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
2005The Journal of rheumatology
PubMed ↗Retroperitoneal fibrosis secondary to spondylodiscitis after infection with Prevotella
2005Rheumatology (Oxford, England)
PubMed ↗Focal myositis with fasciitis and vasculitis revealing chronic lymphocytic leukaemia
2002Joint bone spine
PubMed ↗Bronchiectasis in a patient with CREST syndrome
2008Scandinavian journal of immunology
PubMed ↗B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome
2008Rheumatology (Oxford, England)
PubMed ↗Is Inhibitor of differentiation 3 involved in human primary Sjögren's syndrome?
2007Annals of the rheumatic diseases
PubMed ↗Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus
2006Arthritis research & therapy
PubMed ↗B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome
2006Arthritis research & therapy
PubMed ↗No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome
2006Arthritis and rheumatism
PubMed ↗Failure to confirm coxsackievirus infection in primary Sjögren's syndrome
2005Annals of the rheumatic diseases
PubMed ↗Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome
2005Journal of autoimmunity
PubMed ↗CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome
2004The Journal of pathology
PubMed ↗Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome
2003Annals of the rheumatic diseases
PubMed ↗The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome
2007Haematologica
PubMed ↗Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery
2007Annals of the rheumatic diseases
PubMed ↗Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production
2012Annals of the rheumatic diseases
PubMed ↗Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
2012Annals of the rheumatic diseases
PubMed ↗Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls
2025The Journal of rheumatology
PubMed ↗Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
2007Annals of the rheumatic diseases
PubMed ↗Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus
2025The Journal of rheumatology
PubMed ↗Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
2025Rheumatology (Oxford, England)
PubMed ↗Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS
2025The Journal of rheumatology
PubMed ↗Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
2026Article
Guselkumab Improves Patient-Reported Outcomes Among Participants With Psoriatic Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors in the COSMOS Study
Rheumatology and Therapy
2025Article
Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
Journal of Rheumatology
2024Article
Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS
Rheumatology
2023Article
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
Arthritis Research & Therapy
2023Article
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study
Arthritis Research & Therapy
2023Article
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
Rheumatology
2022Article
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
Annals of the Rheumatic Diseases
2022Article
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
The Lancet Gastroenterology & Hepatology